Micrometastases in non-small cell lung cancer (NSCLC)

被引:0
|
作者
Passlick, B [1 ]
机构
[1] Univ Munich, Klinikum Innenstadt, Dept Surg, Div Thorac Surg, D-80336 Munich, Germany
关键词
micrometastases; NSCLC; immunohistochemical detection; isolated tumor cells; prognosis;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Early metastasis is a well-known Feature of poor prognosis in potentially resectable non-small cell lung cancer (NSCLC). However. a significant number of lymph node-negative patients die early of metastatic disease. Therefore. it has to be assumed that in some patients an early tumor cell dissemination has occurred which is clearly underestimated by current staging procedures. Recently. it has been shown, that an early dissemination of individual carcinoma cells to regional lymph nodes or bone marrow can be detected by using sensitive immunocytochemical techniques with monoclonal antibodies against epithelium-specific proteins, The incidence of immunohistochemically positive patients varies between 30 and 70% depending on the type of primary tumor. the immunohistochemical staining procedure used and especially on the primary monoclonal antibody. The detection of disseminated tumor cells in lymph nodes or bone marrow by immunocytochemistry is associated with a poorer prognosis in lung cancer. In conclusion, the immunohistochemical detection of disseminated tumor cells in lymph nodes can help to obtain a more exact identification of patients with an unfavorable prognosis. Whether the identified patients will gain from an adjuvant therapy, has to be evaluated in further studies. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:S25 / S29
页数:5
相关论文
共 50 条
  • [1] The Clinical Value of Lymphatic Micrometastases in Patients with Non-small Cell Lung Cancer
    Verhagen, Ad F.
    Bulten, Johan
    Shirango, Hebste
    Thunnissen, Frederik B. J. M.
    van der Drift, Miep A.
    van der Bruggen, Wouter
    Tjan-Heijnen, Vivianne C. G.
    van Swieten, Henry A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (08) : 1201 - 1205
  • [2] Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
    Christian Manegold
    Petr Zatloukal
    Kurt Krejcy
    Johannes Blatter
    Investigational New Drugs, 2000, 18 : 29 - 42
  • [3] Gemcitabine in non-small cell lung cancer (NSCLC)
    Manegold, C
    Zatloukal, P
    Krejcy, K
    Blatter, J
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (01) : 29 - 42
  • [4] Hypoxic markers in non-small cell lung cancer (NSCLC) - A review
    Xu, F. -X.
    Zhang, Y. -L.
    Liu, J. -J.
    Zhang, D. -D.
    Chen, H. -B.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (05) : 849 - 852
  • [5] Staging of non-small cell lung cancer (NSCLC): A review
    Tsim, S.
    O'Dowd, C. A.
    Milroy, R.
    Davidson, S.
    RESPIRATORY MEDICINE, 2010, 104 (12) : 1767 - 1774
  • [6] Personalized Therapy of Non-small Cell Lung Cancer (NSCLC)
    Gadgeel, Shirish M.
    LUNG CANCER AND PERSONALIZED MEDICINE: NOVEL THERAPIES AND CLINICAL MANAGEMENT, 2016, 890 : 203 - 222
  • [7] A Pragmatic Approach to the Diagnosis of Nodal Micrometastases in Early Stage Non-small Cell Lung Cancer
    Herpel, Esther
    Muley, Thomas
    Schneider, Thomas
    Palm, Elisa
    de Hol, Doerthe Kieslich
    Warth, Arne
    Meister, Michael
    Storz, Konstantina
    Schnabel, Philipp A.
    Schirmacher, Peter
    Dienemann, Hendrik
    Hoffmann, Hans
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (08) : 1206 - 1212
  • [8] The Evaluation of Serum Biomarkers for Non-small Cell Lung Cancer (NSCLC) Diagnosis
    Fang, Rui
    Zhu, Yong
    Khadka, Vedbar S.
    Zhang, Fan
    Jiang, Bin
    Deng, Youping
    FRONTIERS IN PHYSIOLOGY, 2018, 9
  • [9] Nivolumab in Non-Small Cell Lung Cancer (NSCLC): Facing the Reality
    Merimsky, O.
    Shamai, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2425 - S2425
  • [10] New perspectives in the treatment of non-small cell lung cancer (NSCLC)
    Brockmoeller, Juergen
    Junker, Klaus
    Multhoff, Gabriele
    ONKOLOGIE, 2006, 29 : 25 - 28